...
首页> 外文期刊>Stem cells translational medicine. >Delayed Minimally Invasive Injection of Allogenic Bone Marrow Stromal Cell Sheets Regenerates Large Bone Defects in an Ovine Preclinical Animal Model
【24h】

Delayed Minimally Invasive Injection of Allogenic Bone Marrow Stromal Cell Sheets Regenerates Large Bone Defects in an Ovine Preclinical Animal Model

机译:延迟的最低侵入性的同种异体骨髓基质细胞床单注射再生绵羊临床前动物模型中的大骨缺损。

获取原文
           

摘要

Cell-based tissue engineering approaches are promising strategies in the field of regenerative medicine. However, the mode of cell delivery is still a concern and needs to be significantly improved. Scaffolds and/or matrices loaded with cells are often transplanted into a bone defect immediately after the defect has been created. At this point, the nutrient and oxygen supply is low and the inflammatory cascade is incited, thus creating a highly unfavorable microenvironment for transplanted cells to survive and participate in the regeneration process. We therefore developed a unique treatment concept using the delayed injection of allogenic bone marrow stromal cell (BMSC) sheets to regenerate a critical-sized tibial defect in sheep to study the effect of the cells' regeneration potential when introduced at a postinflammatory stage. Minimally invasive percutaneous injection of allogenic BMSCs into biodegradable composite scaffolds 4 weeks after the defect surgery led to significantly improved bone regeneration compared with preseeded scaffold/cell constructs and scaffold-only groups. Biomechanical testing and microcomputed tomography showed comparable results to the clinical reference standard (i.e., an autologous bone graft). To our knowledge, we are the first to show in a validated preclinical large animal model that delayed allogenic cell transplantation can provide applicable clinical treatment alternatives for challenging bone defects in the future.
机译:基于细胞的组织工程方法是再生医学领域中有希望的策略。然而,细胞递送的方式仍然是一个问题,需要显着改善。通常,在产生缺陷的支架和/或装有细胞的基质后立即将其移植到骨缺损中。在这一点上,营养和氧气供应不足,并引发了炎症级联反应,从而为移植细胞存活和参与再生过程创造了非常不利的微环境。因此,我们开发了一种独特的治疗概念,即使用异体骨髓基质细胞(BMSC)的延迟注射来再生绵羊的临界大小的胫骨缺损,以研究在炎症后阶段引入时细胞再生潜力的影响。与预先植入的支架/细胞构建体和仅支架组相比,缺损手术后4周将同种异体BMSC微创经皮注射到可生物降解的复合支架中可显着改善骨骼再生。生物力学测试和微计算机断层扫描显示的结果与临床参考标准(即自体骨移植物)相当。据我们所知,我们是第一个在经过验证的临床前大型动物模型中证明,延迟异体细胞移植可以为将来挑战骨缺损提供可替代的临床治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号